Table 3. HIV pre-treatment drug resistance by year of enrolment.
| Year | n | Any ARV Drug | NNRTI PDR | NRTI PDR | PI PDR | NRTI + NNRTI PDR |
|---|---|---|---|---|---|---|
| 2011 | 17 | 5.9 (0.1, 28.7) | 0.0 (0.0, 19.5) | 5.9 (0.1, 28.7) | 0.0 (0.0, 19.5) | 0.0 (0.0, 19.5) |
| 2012 | 88 | 18.2 (10.8, 27.8) | 8.0 (3.3, 15.7) | 6.8 (2.5, 14.3) | 4.5 (1.3, 11.2) | 1.1 (0.0, 6.2) |
| 2013 | 69 | 20.3 (11.6, 31.7) | 14.5 (7.2, 25.0) | 7.2 (2.4, 16.1) | 1.4 (0.0, 7.8) | 2.9 (0.4, 10.1) |
| 2014 | 61 | 18.0 (9.4, 30.0) | 11.5 (4.7, 22.2) | 4.9 (1.0, 13.7) | 1.6 (0.0, 8.8) | 0.0 (0.0, 5.9) |
| 2015 | 48 | 27.1 (15.3, 41.8) | 16.7 (7.5, 30.2) | 8.3 (2.3, 20.0) | 4.2 (0.5, 14.3) | 2.1 (0.1, 11.1) |
| p-valuea | 0.0536 | 0.0422 | NS | NS | NS | |
| 2011–2015 | 283 | 19.4 (15.0, 24.5) | 11.3 (7.9, 15.6) | 6.7 (4.1, 10.3) | 2.8 (1.2, 5.5) | 1.4 (0.4, 3.6) |
a Linear regression (slope significantly different to zero) for each drug class. HIVDR defined with the HIVdb tool, using Sanger sequences. NS, non-significant (p>0.05).